Inventor · disambiguated record
Julie Kay Cahill
Also filed as: CAHILL JULIE · CAHILL JULIE K · CAHILL JULIE KAY
6 granted patents·13 pending applications·29 citations·filing 2001–2024
81Inventor score
Top patents by PatentIndex Score
19 records- 0196US11633396B2Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-oneKUDOS PHARM LTD·Filed 2022·Granted Apr 25, 2023·8 cites·30 claims
- 0290US12178816B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2024·Granted Dec 31, 2024·0 cites·30 claims
- 0390US12144810B1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2024·Granted Nov 19, 2024·0 cites·30 claims
- 0490US8475842B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneBECHTOLD MICHAEL KARL·Filed 2009·Granted Jul 2, 2013·21 cites·10 claims
- 0586US12048695B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2023·Granted Jul 30, 2024·0 cites·10 claims
- 0686US11975001B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2023·Granted May 7, 2024·0 cites·13 claims
- 0778US2022249474A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneKUDOS PHARM LTD·Filed 2021·Application pending·0 cites
- 0872US2020323847A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2020·Application pending·0 cites
- 0969US2019365751A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2018·Application pending·0 cites
- 1065US2018133216A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2017·Application pending·0 cites
- 1164US2017173010A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2017·Application pending·0 cites
- 1263US2014066447A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2013·Application pending·0 cites
- 1358US2016008473A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2015·Application pending·0 cites
- 1443US2004138299A1Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2hydroxy-methylpropiono-m toluidide and pvpCAHILL JULIE·Filed 2002·Application pending·0 cites
- 1541US2004138231A1Pharmaceutical composition which comprise a solid dispersion of a hydroxypropyl-methylcellulose phthalate polymerFiled 2002·Application pending·0 cites
- 1641US2004076673A1Oral pharmaceutical composition containing a block copolymerFiled 2001·Application pending·0 cites
- 1739US2006058381A1Pharmaceutical formulation comprising (r)-bicalitamideASTRAZENECA AB·Filed 2002·Application pending·0 cites
- 1838US2009028943A1Pharmaceutical compositionsCAHILL JULIE KAY·Filed 2006·Application pending·0 cites
- 1938US2005038111A1Pharmaceutical formulation comprising bicalutamideASTRAZENECA AB·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Julie Kay Cahill files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →